Literature DB >> 32213428

An updated role of astragaloside IV in heart failure.

Yibei Zang1, Jingjing Wan2, Zhen Zhang3, Si Huang3, Xia Liu4, Weidong Zhang5.   

Abstract

Heart failure (HF) has become a worldwide public health problem that seriously threatens human's health. Due to "multi-target" effect, traditional Chinese medicine (TCM) has unique advantages in this field. Chinese herb-derived active components would provide valuable candidate compounds for new drug development. Astragaloside IV(AS-IV) is a main effective ingredient of Astragalus membranaceus, a commonly used Chinese patent medicine for the patients with chronic heart failure(CHF). Our aim is to review the recent progresses of AS-IV in HF, and provide potential evidence for its clinical application. Data showed that AS-IV could protect myocardial ischemia, regulate sarcoplasmic reticulum Ca2+ pump, promote angiogenesis, improve energy metabolism, inhibit cardiac hypertrophy and fibrosis, reduce myocardial cell apoptosis, etc, which are direct or indirect involved in the beneficial effects of AS-IV in rodents or cellular models of HF. AS-IV or its derivatives may act as a potential therapeutic drug in the clinical treatment of HF.
Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Astragaloside IV; Heart failure; Pharmacological effect; Traditional Chinese medicine

Mesh:

Substances:

Year:  2020        PMID: 32213428     DOI: 10.1016/j.biopha.2020.110012

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  11 in total

1.  Astragaloside IV inhibits adriamycin-induced cardiac ferroptosis by enhancing Nrf2 signaling.

Authors:  Li-Fei Luo; Peng Guan; Lu-Yun Qin; Jian-Xin Wang; Na Wang; En-Sheng Ji
Journal:  Mol Cell Biochem       Date:  2021-03-03       Impact factor: 3.396

2.  Investigation of the Mechanism of Traditional Chinese Medicines in Angiogenesis through Network Pharmacology and Data Mining.

Authors:  Wingyan Yun; Wenchao Dan; Jinlei Liu; Xinyuan Guo; Min Li; Qingyong He
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-28       Impact factor: 2.629

3.  A Network Pharmacology-Based Approach to Investigating the Mechanisms of Fushen Granule Effects on Intestinal Barrier Injury in Chronic Renal Failure.

Authors:  Miaoru Han; Hangxing Yu; Kang Yang; Panying Liu; Haifeng Yan; Zhihua Yang; Hongtao Yang
Journal:  Evid Based Complement Alternat Med       Date:  2021-03-05       Impact factor: 2.629

4.  Astragaloside IV Ameliorates Myocardial Infarction Induced Apoptosis and Restores Cardiac Function.

Authors:  Chuang Sun; Guangwei Zeng; Tingting Wang; He Ren; Huixian An; Cheng Lian; Jing Liu; Li Guo; Wei Li
Journal:  Front Cell Dev Biol       Date:  2021-07-29

5.  Schisandrin A protects against isoproterenol‑induced chronic heart failure via miR‑155.

Authors:  Lijing Gao; Ting Li; Shufen Li; Zhuohui Song; Yongli Chang; Li Yuan
Journal:  Mol Med Rep       Date:  2021-11-23       Impact factor: 2.952

6.  Astragaloside IV Reduces OxLDL-Induced BNP Overexpression by Regulating HDAC.

Authors:  Wenting Zhang; Xin Wang; Jing Li; Mingyuan Xu; Xiaolu Ren; Huiying Liu; Lu Xu; Jun Shao
Journal:  J Healthc Eng       Date:  2021-12-03       Impact factor: 2.682

7.  Astragaloside positively regulated osteogenic differentiation of pre-osteoblast MC3T3-E1 through PI3K/Akt signaling pathway.

Authors:  Wei Bing Jing; Hongjuan Ji; Rui Jiang; Jinlong Wang
Journal:  J Orthop Surg Res       Date:  2021-10-07       Impact factor: 2.359

Review 8.  Chinese Herbal Medicine Alleviates Myocardial Ischemia/Reperfusion Injury by Regulating Endoplasmic Reticulum Stress.

Authors:  Wu-Lin Liang; Meng-Ru Cai; Ming-Qian Zhang; Shuang Cui; Tian-Rui Zhang; Wen-Hao Cheng; Yong-Hong Wu; Wen-Jing Ou; Zhan-Hong Jia; Shuo-Feng Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-07       Impact factor: 2.629

9.  Astragaloside IV promotes pharmacological effect of Descurainia sophia seeds on isoproterenol-induced cardiomyopathy in rats by synergistically modulating the myosin motor.

Authors:  Xingkai Liu; Qian Chen; Xuming Ji; Wanchen Yu; Tong Wang; Juanjuan Han; Shumu Li; Jianan Liu; Fangang Zeng; Yao Zhao; Yanyan Zhang; Qun Luo; Shijun Wang; Fuyi Wang
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

10.  Puerarin attenuates isoproterenol‑induced myocardial hypertrophy via inhibition of the Wnt/β‑catenin signaling pathway.

Authors:  Xiaoying Wang; Kai He; Linlin Ma; Lan Wu; Yan Yang; Yanfei Li
Journal:  Mol Med Rep       Date:  2022-08-10       Impact factor: 3.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.